ANIX

Anixa Biosciences, Inc. operates as a biotechnology company focused on developing therapies and vaccines in the areas of cancer and infectious diseases. Headquartered in San Jose, California, the company pursues two primary platforms: cancer immunotherapy and vaccine development. Anixa's oncology portfolio includes chimeric endocrine receptor T-cell (CER-T) technology for breast and ovarian cancers, developed in partnership with the Moffitt Cancer Center, and a cancer vaccine targeting multiple tumor-associated antigens in collaboration with Cleveland Clinic. The company's infectious disease work centers on a vaccine candidate against COVID-19 variants, also developed with Cleveland Clinic. As a clinical-stage biopharmaceutical company, Anixa does not generate product revenue and relies on funding through equity offerings and strategic partnerships to advance its pipeline. The company maintains collaborative research agreements with leading academic medical centers rather than owning extensive internal infrastructure. Recent developments include progress in preclinical and early clinical studies for its CER-T technology and advancement of its ovarian cancer vaccine through Phase 1 trials. Anixa trades on the NASDAQ under the ticker symbol ANIX. The company's strategy emphasizes leveraging partnerships with renowned research institutions to develop innovative therapies while maintaining a capital-efficient operating model focused on translating promising research into clinical applications.